John D. Lueck

This paper demonstrates that DNA-based ACE-tRNA minivectors effectively suppress nonsense mutations in CFTR and REP1, with improved bioavailability and stability compared to plasmid DNA vectors.

The paper demonstrates that ACE-tRNAs enable readthrough of COL4A5 nonsense variants, restoring full-length protein expression and heterotrimer formation in cell models of Alport syndrome.

This study shows that removing a specific splice variant of ClC-1 in a DM1 mouse model eliminates myotonia and improves muscle function and histology.

GZESTY is a cell-based assay for Gi/o/z-coupled GPCRs that detects ligand activation and identifies endogenous ligands for orphan GPCRs.

This paper investigates how PTC identity and sequence context affect readthrough efficiency and ataluren's effectiveness, providing insights into patient-specific therapy design.

This study optimizes ACE-tRNA function to suppress nonsense mutations, reducing the required amount by ~16-fold for common cystic fibrosis-causing PTCs.

The paper demonstrates that ACE-tRNAs can suppress nonsense mutations in CF by rescuing CFTR transcript abundance and channel function in multiple models.

Anticodon engineered tRNAs suppress CFTR nonsense mutations, increasing mRNA expression and channel function in human cells.

The paper investigates the role of β11-12 linker isomerization in ASIC desensitization and recovery using electrophysiology, simulations, and cross-linking.

This paper identifies engineered transfer RNAs (ACE-tRNA) that suppress premature termination codons in mammalian cells and mice, showing high suppression activity for common disease-causing nonsense codons.